Equities analysts forecast that Spark Therapeutics Inc (NASDAQ:ONCE) will announce $27.71 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Spark Therapeutics’ earnings, with the lowest sales estimate coming in at $26.92 million and the highest estimate coming in at $28.50 million. Spark Therapeutics reported sales of $25.19 million during the same quarter last year, which indicates a positive year over year growth rate of 10%. The business is expected to announce its next earnings report on Tuesday, August 27th.
On average, analysts expect that Spark Therapeutics will report full year sales of $119.12 million for the current financial year, with estimates ranging from $72.80 million to $157.06 million. For the next financial year, analysts anticipate that the business will report sales of $139.14 million, with estimates ranging from $137.00 million to $141.27 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Spark Therapeutics.
Several equities analysts have commented on the stock. Zacks Investment Research downgraded shares of Spark Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, August 14th. Mizuho reaffirmed a “hold” rating and issued a $114.50 price target on shares of Spark Therapeutics in a research report on Monday, August 12th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $87.92.
Large investors have recently modified their holdings of the company. Sterling Investment Advisors Ltd. bought a new position in Spark Therapeutics in the first quarter worth about $68,000. CSat Investment Advisory L.P. bought a new position in shares of Spark Therapeutics during the second quarter valued at $113,000. Meeder Asset Management Inc. bought a new position in shares of Spark Therapeutics during the first quarter valued at $121,000. Janney Montgomery Scott LLC bought a new position in shares of Spark Therapeutics during the second quarter valued at $202,000. Finally, Ancora Advisors LLC bought a new position in shares of Spark Therapeutics during the second quarter valued at $205,000. 81.40% of the stock is currently owned by institutional investors.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells.
Further Reading: Does the discount rate affect the economy?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.